Literature DB >> 19259301

The Quality of Quality-of-Life and Cost-Effectiveness Analyses.

Derek G Power1, David P Kelsen, Manish A Shah.   

Abstract

Year:  2008        PMID： 19259301      PMCID： PMC2630823     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  18 in total

1.  Chemotherapy in gastric cancer: a review and updated meta-analysis.

Authors:  Karl-Gunnar Janunger; Larsolof Hafström; Bengt Glimelius
Journal:  Eur J Surg       Date:  2002

2.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

3.  Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.

Authors:  D J Stewart; S Dahrouge; D Coyle; W K Evans
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

Review 4.  Role of radiation therapy in gastric adenocarcinoma.

Authors:  Lisa Hazard; John O'Connor; Courtney Scaife
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

5.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

6.  Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.

Authors:  Florian Lordick; Birgit Ehlken; Angela Ihbe-Heffinger; Karin Berger; Karl J Krobot; James Pellissier; Glenn Davies; Robert Deuson
Journal:  Eur J Cancer       Date:  2006-11-28       Impact factor: 9.162

7.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

Authors:  Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg
Journal:  J Clin Oncol       Date:  2006-05-22       Impact factor: 44.544

8.  Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.

Authors:  Vincent Caggiano; Richard V Weiss; Timothy S Rickert; Walter T Linde-Zwirble
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

9.  Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.

Authors:  Sorrel E Wolowacz; David A Cameron; Helen C Tate; Adrian Bagust
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

10.  Adjuvant therapy for resected gastric cancer--rapid, yet incomplete adoption following results of intergroup 0116 trial.

Authors:  Natalie G Coburn; Ulrich Guller; Nancy N Baxter; Alex Kiss; Jolie Ringash; Carol J Swallow; Calvin H L Law
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-01       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.